Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder September 14, 2026 Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference August 25, 2026 Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones July 30, 2026 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry June 30, 2026 Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference June 1, 2026 Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 15, 2026 Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference May 12, 2026 Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference May 11, 2026 Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones May 5, 2026 Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder September 14, 2026
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference August 25, 2026
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones July 30, 2026
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry June 30, 2026
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference June 1, 2026
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference May 12, 2026
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference May 11, 2026
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones May 5, 2026
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)